
    
      This will be a multi-center, double-blind, placebo controlled, parallel, 12 week treatment
      trial in men with signs and symptoms of benign prostatic hyperplasia. The following
      procedures are utilized: physical exams, electrocardiograms, clinical laboratory tests, vital
      signs, the International Prostate Symptom Score, maximum urine flow rate, pharmacokinetics,
      adverse events, concomitant medications, quality of life, and compliance.
    
  